Samsung Biologics wins nearly full backing in PolyPeptide tender offer
Samsung Biologics' booth at BIO USA 2025 Samsung Biologics Co., South Korea's largest contract drug manufacturer, raised its full-year revenue growth forecast after sales rose…
TR
By Tom Reyes · Markets Editor
Nov 2 03:10 ETSource: KED Global
From the source
Read at kedglobal.comSamsung Biologics wins nearly full backing in PolyPeptide tender offer
Samsung Biologics' booth at BIO USA 2025 Samsung Biologics Co., South Korea's largest contract drug manufacturer, raised its full-year revenue growth forecast after sales rose 18.5% in the third quarter, as the company began to recognize more revenue from a US manufacturing facility it acquired
